Complement, innate immunity and ocular disease
- PMID: 17264487
- DOI: 10.1159/000099261
Complement, innate immunity and ocular disease
Abstract
The complement system is a major component of innate immunity. During an inflammatory reaction, the eye is potentially threatened by homologous complement attack, and unregulated complement activation could lead to tissue damage and vision loss. The complement system is continuously activated at low levels in the normal eye, and intraocular complement-regulatory proteins (CRPs) tightly regulate this spontaneous complement activation so that there is elimination of potential pathogens without the induction of destructive intraocular inflammation. The presence of a complement activation product (iC3b) during the early phase of antigen and antigen-presenting cell contact is essential for the induction of systemic tolerance to antigen injected into the anterior chamber of the eye and the establishment of ocular immune privilege. The complement system and complement-regulatory proteins control intraocular inflammation in autoimmune anterior uveitis and may play an important role in the development of age-related macular degeneration. Thus, in the eye, complement functions as a double-edged sword - on one hand it provides innate immunity against pathogens while simultaneously instructing the adaptive immune response to develop tolerance to such pathogens to avoid inadvertent tissue damage in a critical organ.
Similar articles
-
The link between morphology and complement in ocular disease.Mol Immunol. 2017 Sep;89:84-99. doi: 10.1016/j.molimm.2017.05.028. Epub 2017 Jun 15. Mol Immunol. 2017. PMID: 28622910 Review.
-
The role of complement system in ocular diseases including uveitis and macular degeneration.Mol Immunol. 2007 Sep;44(16):3901-8. doi: 10.1016/j.molimm.2007.06.145. Mol Immunol. 2007. PMID: 17768108 Free PMC article. Review.
-
Doyne lecture 2016: intraocular health and the many faces of inflammation.Eye (Lond). 2017 Jan;31(1):87-96. doi: 10.1038/eye.2016.177. Epub 2016 Sep 16. Eye (Lond). 2017. PMID: 27636226 Free PMC article. Review.
-
Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.Ocul Immunol Inflamm. 2010 Dec;18(6):488-92. doi: 10.3109/09273948.2010.525730. Ocul Immunol Inflamm. 2010. PMID: 21091058 Free PMC article.
-
The role of complement in ocular pathology.Semin Immunopathol. 2008 Apr;30(2):85-95. doi: 10.1007/s00281-008-0110-y. Epub 2008 Feb 26. Semin Immunopathol. 2008. PMID: 18299835 Free PMC article. Review.
Cited by
-
Low-molecular weight inhibitors of the alternative complement pathway.Immunol Rev. 2023 Jan;313(1):339-357. doi: 10.1111/imr.13143. Epub 2022 Oct 11. Immunol Rev. 2023. PMID: 36217774 Free PMC article. Review.
-
PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2518-25. doi: 10.1167/iovs.07-1606. Epub 2008 Feb 22. Invest Ophthalmol Vis Sci. 2008. PMID: 18296654 Free PMC article.
-
Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression.EBioMedicine. 2018 Feb;28:274-286. doi: 10.1016/j.ebiom.2018.01.024. Epub 2018 Jan 31. EBioMedicine. 2018. PMID: 29398596 Free PMC article.
-
Parainflammation, chronic inflammation, and age-related macular degeneration.J Leukoc Biol. 2015 Nov;98(5):713-25. doi: 10.1189/jlb.3RI0615-239R. Epub 2015 Aug 20. J Leukoc Biol. 2015. PMID: 26292978 Free PMC article. Review.
-
Immune mechanisms in inflammatory and degenerative eye disease.Trends Immunol. 2015 Jun;36(6):354-63. doi: 10.1016/j.it.2015.04.003. Epub 2015 May 13. Trends Immunol. 2015. PMID: 25981967 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical